Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Company Overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. In addition to this marketed asset, Lexicon maintains a diversified pipeline with programs spanning metabolic diseases, neuropathic pain, and rare genetic disorders. Key development candidates include small-molecule inhibitors modulating glucose transport and neuroreceptor activity, each designed to address unmet medical needs through precise mechanism-based intervention.

Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has been publicly traded on the NASDAQ exchange since 2000. The company collaborates with academic institutions, strategic partners and patient advocacy groups to advance its research and expand clinical development globally. With a core scientific team experienced in genomics, medicinal chemistry and clinical development, Lexicon continues to pursue innovative solutions aimed at improving patient outcomes across a variety of therapeutic areas.

Key Stats

• Today's Range: $1.48 to $1.61
• 50-Day Range: $1.02 to $1.55
• 52-Week Range: $0.28 to $2.18
• Volume: 4.05 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $552.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.23
• Consensus Rating: Hold

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

Lexicon Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 417th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Lexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Lexicon Pharmaceuticals has a consensus price target of $3.23, representing about 112.2% upside from its current price of $1.52.

Amount of Analyst Coverage

Lexicon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexicon Pharmaceuticals is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexicon Pharmaceuticals is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexicon Pharmaceuticals has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.81% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 1.60%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexicon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Lexicon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.81% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 1.60%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Lexicon Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lexicon Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.90% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LXRX Stock Analysis - Frequently Asked Questions

How have LXRX shares performed this year?

Lexicon Pharmaceuticals' stock was trading at $0.7385 at the beginning of 2025. Since then, LXRX stock has increased by 105.8% and is now trading at $1.52.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The biopharmaceutical company had revenue of $28.87 million for the quarter, compared to analyst estimates of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative trailing twelve-month return on equity of 83.63%.
Read the conference call transcript.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXRX
• Previous Symbol: NASDAQ:LEXG
• CIK: 1062822
• Web: www.lexpharma.com
• Phone: (281) 863-3000
• Fax: 281-863-8010
• Employees: 140
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Lexicon Pharmaceuticals: $3.23
• High Price Target: $6.00
• Low Price Target: $1.00
• Potential Upside/Downside: +112.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$200.40 million
• Net Margins: -206.43%
• Pretax Margin: -206.43%
• Return on Equity: -83.63%
• Return on Assets: -42.22%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 4.16
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: $31.08 million
• Price / Sales: 17.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 3.80

Miscellaneous

• Outstanding Shares: 363,400,000
• Free Float: 312,887,000
• Market Cap: $552.37 million
• Optionable: Optionable
• Beta: 1.23